Two pharmaceutical companies on the same day "shot" siege of 5 billion varieties.

Pharmaceutical Network August 17th, August 12th, Hainan Bett Pharmaceuticals, Wuhan Qirui Pharmaceuticals to imitate the 4 categories submitted by the injection of Voliconazole listing application was accepted by CDE.
2019, China's public medical institutions terminal antifungal antifungal drug TOP10 products, injection of volicazole with 29% of the market share in the first place.
Figure 1: August 12 injection with voliconazole contractor source: CDE official website Voliconazole is a broad spectrum of triamcinolone antifungal drugs, can inhibit the biosynthesis of the fungus mcprentol and play an antifungal role, candida, trimycinol and other fungi have a bactericidal effect, is the treatment of serious trimycin infection of the first-line drugs.
the current domestic market sales of the main dosage form of Voliconazole capsules, tablets, injections, dry suspension and so on. according to
meters intranet data, in 2019 China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (China's public medical institutions) terminals Voliconzo sales of more than 5 billion yuan, of which injections exclusively "half of the wall."
in the whole body antifungal drug TOP10 products, injection volicazole with 29% of the market share in the first place.
At present, there are 5 enterprises in the domestic market with injection of Volliconazole production approval, no enterprise's products have been evaluated, nor have enterprises submitted a consistent evaluation supplementary application, but 7 enterprises to copy 4 categories to submit the product listing application, if approved for listing, will be treated as through consistency evaluation.
Figure 2: New classification of voliconazole for injection source: Minet one-click search from the contractor date, Qilu Pharmaceuticals in July 2018 the first to submit a new classification of the market application for injection volicazole, Hainan Puli Pharmaceutical followed immediately.
, Hainan Pte Pharmaceuticals submitted an application for the product to be launched in August 2019 and again on August 12, 2020, presumably for new product planning.
source: In-net database note: data statistics as of August 14, if there are omissions, welcome to point the right!